STML-ELA-0422 Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence—A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)
- Phase III
- Trial Category: Breast
Contact(s)
Mary Beth Wilwerding, RN Admin@NEcancertrials.com
Location(s)
Available at Nebraska Cancer Specialists, Omaha and Grand Island, NE locations and at Nebraska Hematology and Oncology, Lincoln, NE location
Interested in More Information?
Please fill out the form below. Someone will get back to you as soon as possible.
"*" indicates required fields